<DOC>
	<DOCNO>NCT03095287</DOCNO>
	<brief_summary>This multicenter , multinational , prospective , single-arm , nonrandomized , open-label study approximately 25 male subject congenital hemophilia A receive first ( primary ) immune tolerance induction ( ITI ) treatment Alphanate . The study consist 2 phase : - An ITI Treatment Phase eligible subject receive ITI treatment Alphanate period 33 month . Upon confirmation complete immune tolerization , subject enter 12-month Prophylactic Phase . If , 33 month ITI , subject achieve partial immune tolerance , subject enter 12-month Prophylactic Phase . - A 12-month Prophylactic Phase subject meet criterion complete partial success continue prophylactic dose regimen Alphanate .</brief_summary>
	<brief_title>Alphanate Immune Tolerance Induction Therapy</brief_title>
	<detailed_description>Male subject &lt; 8 year age present inhibitor titer &gt; 0.6 &lt; 10 Bethesda Units ( BU ) screen planned start ITI treatment . Subjects continue meet entrance criterion enter ITI Treatment Phase receive daily dos Alphanate 100 IU/kg/day 33 month , one-time option increase dose regimen 200 IU/kg/day time 90 day ITI treatment . Subjects continue receive daily Alphanate dose 33 month titer negative ( &lt; 0.6 BU ) 2 consecutive assessment treatment success confirm FVIII : C pharmacokinetic assessment , time enter 12 month Prophylactic Phase . In addition , subject achieve partial immune tolerance completion 33 month ITI treatment enter 12-month Prophylactic Phase . Subjects achieve partial immune tolerance completion 33 month ITI treatment discontinue treatment failure . The Prophylactic Phase begin 8 week taper period subject tolerized 100 IU/kg/day 12-week taper period subject tolerized 200 IU/kg/day bring dose step-wise manner prophylactic dose Alphanate 50 IU/kg every day 3 time per week , investigator 's discretion . During Prophylactic Phase , subject monitor monthly first 4 month every 2 month remain 8 month assess sustainability immune tolerance .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>The subject document diagnosis severe congenital hemophilia A FVIII : C &lt; 1 % normal . The subject male &lt; 8 year age ( least 2 year age India ) Baseline Visit . The subject 's documented historical peak inhibitor titer ≥10 BU ≤200 BU . The subject inhibitor titer &gt; 0.6 BU &lt; 10 BU Screening . The subject delay ≤24 month date diagnosis inhibitor start subject 's ITI treatment . The subject acquire factor VIII ( FVIII ) deficiency . The subject previously receive ITI treatment . The subject recent ( within 1 month ) history central line infection time Screening . The subject high risk cardiovascular , cerebrovascular , thromboembolic event judge investigator . The subject currently undergo treatment immunosuppressive drug ( eg , systemic corticosteroid ) , azathioprine , cyclophosphamide , high dose immunoglobulin , interferon , use protein A column plasmapheresis unwilling discontinue treatment start screen visit . The subject know infection human immunodeficiency virus ( HIV ) clinical sign symptoms consistent current HIV infection . The subject know previous infection hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) clinical sign symptoms consistent current HBV HCV infection . The subject significant proteinuria , history acute renal failure severe renal impairment ( blood urea nitrogen creatinine &gt; 2 time upper limit normal ) , receive dialysis Screening . The subject value aspartate transaminase alanine aminotransferase &gt; 2 time upper limit normal Screening . The subject clinical evidence significant acute chronic disease , opinion investigator , may interfere successful completion trial place subject undue medical risk . The subject history anaphylaxis severe systemic reaction plasma derive blood product .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Factor VIII</keyword>
	<keyword>von Willebrand Factor</keyword>
	<keyword>Plasma-derived</keyword>
	<keyword>Inhibitors</keyword>
	<keyword>Immune tolerance induction</keyword>
	<keyword>ITI</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Hemophilia A</keyword>
</DOC>